Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Michael Hallek(University of Cologne), Bruce D. Cheson(Georgetown University), Daniel Catovsky(Institute of Cancer Research), Federico Caligaris‐Cappio(Istituti di Ricovero e Cura a Carattere Scientifico), Guillaume Dighiero(Institut Pasteur de Montevideo), Hartmut Döhner(Universität Ulm), Peter Hillmen(St James's University Hospital), Michael J. Keating(The University of Texas MD Anderson Cancer Center), Emili Montserrat(Hospital Clínic de Barcelona), Kanti R. Rai(Long Island Jewish Medical Center), Thomas J. Kipps(University of California San Diego)
Blood
January 23, 2008
10.1182/blood-2007-06-093906
Cited by 3,188Open Access
Full Text

Abstract

Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute-sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.

Related Papers

No related papers found

Powered by citation graph analysis